Scott D. Collins - Concepedia

Concepedia

Author

Scott D. Collins

Mersana Therapeutics (United States)ORCID

Also Known As

Collins, S, S COLLINS, S. Collins, S.D. Collins, Scott Collins, Scott D Collins, Scott D. Collins, Scott David Collins

87

Publications

1.8K

Citations

12

H-Index

43

Concepts

All Affiliations

Mersana Therapeutics (United States)Novartis (Switzerland)Novartis Institutes for BioMedical Research

SD

About

Scott D. Collins is an author at Mersana Therapeutics (United States) specializing in medicine, radiation oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.6K
2	Engineering	1	1	33
3	Health Sciences	1	1	1.4K
4	Social Sciences	1	1	41
5	Allergy	1	1	25

Scott D. Collins

×

12

Publications

1.8K

Citations

11

H-Index

	Year	Citations
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response Hui Gao, Joshua M. Korn, Stéphane Ferretti, Nature Medicine Tumor BiologyRadiologyOncologyCancer DetectionCancer Screening	2015	1.4K
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Cancer Research	2013	87
Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers Carl Uli Bialucha, Scott D. Collins, Xiao Li, Cancer Discovery	2017	52
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid, Journal of Medicinal Chemistry	2023	44
HALOPERIDOL, CLOPENTHIXOL, AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA E. A. Serafetinides, Scott D. Collins, Mervin L. Clark The Journal of Nervous and Mental Disease Psychoactive DrugPsychiatryPsychotic DisorderMedicineCx Group	1972	41
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer Dorin Toader, Shawn P. Fessler, Scott D. Collins, Molecular Cancer Therapeutics EngineeringImmunologyImmunotherapeuticsImmunotherapyTumor Biology	2023	33
Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas, Cancer Research Minimal InductionImmunologyImmunologic MechanismBiological TherapyInnate Immunity	2020	25
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research ImmunologyImmunoeditingNovel EpitopeImmunotherapeuticsSting Agonist	2022	24
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research NanotherapeuticsAbstract 1738ImmunologyImmunoeditingSting Pathway	2021	23
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster, Clinical Cancer Research	2025	20

Page 1